A recent study effective in Japan indicates acne that B12 treatment helps in the growth scar and division treatments of certain immune system cells.11 These cells effective function to prevent the immune system from over-reacting to allergens such as animals, mold, acne dust, and pollen. They are called suppressor cells or CD8+ lymphocytes. They “put the brakes on the immune system”. scar this medicationTM is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM may help patients treatments with hay fever by providing the patient’s suppressor cells with the sustained and elevated effective and acne blood B12 level they need to grow and divide. It appears scar that by helping the immune system to become what it is genetically capable of becoming, this medicationTM turns at least some allergic people into non-allergic or moderately-allergic people.

All treatments of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or effective a worsening of symptoms. acne Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = scar .005 for IgE reductions. treatments In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction effective in IgE and that a quantitative acne drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication scar with 1.5 mg of oral cyanocobalamin. treatments In four of the five patients treated, bronchospasm effective did not acne develop in the second metabisulfite challenge.6

With no further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen period in Oregon, Washington and Idaho together showed a greater reduction in the active group (n=43) than the placebo group (n=49) on the primary endpoint, defined scar as a combination of treatments symptom effective and rescue medication scores.8 Patients gave blood serum samples prior to the treatment in 1995 acne and one year later in 1996. They were immunoassayed for specific IgE antibodies scar and treatments using a chemi-luminescent technique. Statistician Bradley Rosebrook effective ran T-Tests comparing average baseline IgE levels acne to one-year. For the seasonal scar allergens reported, the active group (n=27) treatments had on average a greater reduction in IgE than the placebo group (n=34) for 13 out of 16 allergens.8

©2003 www.female-prenatal-supplements.com All rights reserved.